ROARABLE
FREE $100K
My Trading Account β†’
β–Ύ
Trading Profile Active
Active Trader
Verified Trader
⚑ My $100K Trading Account β†’ β˜… My Saved Watchlist β†’
🟒 My $100K Account β†’ Today Screener Big Ideas Track Record πŸ’° $100K Arena 🎲 Predictions πŸ›οΈ Insiders 8 Analysts
Stock Ratings / Health Care / CTKB
PACB (44) NAUT (43) ALMR (55) LAB (27) ⌘ Pro Terminal β†’

Cytek Biosciences Inc. (CTKB) β€” RQD Stock Rating Cockpit

$5.77 -5.87% NASDAQ β€’ Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $5.70

Cytek Biosciences Inc. (CTKB) carries a Roarable Rating of D (Sell) with 45/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D β€’ SELL / AVOID Cap $796.8M
πŸ“€ Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚑ INSTANT AI QUANT PREVIEW β€’ $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on CTKB Below β€” or Connect Your Own ChatGPT / Claude
πŸ€– Mara Quenwick β€’ AI Quant Lead (Click for Instant Brief) Is CTKB stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
β–Ό

As of 2026-11-03, Cytek Biosciences Inc. (NASDAQ: CTKB) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 45/100 at a spot price of $5.77 (-5.87% 1D, market cap $796.8M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 16/20, SEC Balance-Sheet Forensics 11/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, CTKB ranks #363 in composite RQD confidence.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Ellis Vennor β€’ AI Peer & Flow Quant (Click for Instant Brief) How does CTKB compare to PACB and NAUT in the Health Care sector?
β–Ό

Within the Health Care sector (Biotechnology: Laboratory Analytical Instruments), CTKB carries a Roarable D (45/100 RQD), trailing P/E of N/A, gross margin of 51.8%, and ROIC of -12.7%. By comparison, PACB (Pacific Biosciences of California Inc.) holds a D grade (44/100 RQD, P/E N/A, ROIC -35.0%, cap $809.7M) and NAUT (Nautilus Biotechnology Inc.) posts a D- grade (43/100 RQD, P/E N/A, ROIC -35.0%, cap $347.7M). Among the 5-stock peer group, CTKB leads on earnings multiple (N/A) while CTKB leads on capital efficiency (-12.7% ROIC).

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Gideon Ashmere β€’ AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for CTKB?
β–Ό

Per CTKB's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001831915), Cytek Biosciences Inc. generated $201.5M in revenue (+0.5% YoY), -$66.5M in net income, and -$8.8M in free cash flow against $461.5M in total assets and $0 in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists β€” not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
πŸ›‘οΈ Portfolio Crash X-Ray
EXT / AFTER-HRS: $5.70 (-1.25%)🧬 Dilution Drag (+2.48% YoY Shares)βš™οΈ Cash Engine: 7/20 (D-) β€’ 0% FCF Margin
Verify 90D Bucket Audit β†’
πŸ“Š Historical Track Record Warning: Scores below 50 (45/100 Β· D) historically underperformed SPY in 71% of rolling 90-day windows (-6.3% avg 90D alpha vs SPY β€’ 29.0% hit rate).
Audit Bucket Track Record β†’
RQD QUANT TACHOMETERSELL / AVOID β€’ D
025507510045
2-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) β€” not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw D- Β· Rk D
Cash (7)Whales (16)SEC (11)Macro (8)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-5.9% Base Target
$7 Bull$5 Base$4 Bear
πŸ“¬ FREE CTKB RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: β€” (No Active Options Snapshot on file for CTKB)Realized 20D OHLCV Swing Band: Β±10.3%
Deterministic 5-Pillar Attribution (45/100 Composite)
πŸ” WHY CTKB SCORES 45/100 (D) β€” TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
β–² #1 Bullish Driver: Whale & Options Positioning+16/20 pts (36% of score)

20D Institutional Volume Accumulation (Β±10.3% realized swing band)

β–² #2 Bullish Driver: SEC 10-K Forensic Risk+11/20 pts (24% of score)

Altman Z-Score 4.76 (FORTRESS SAFE (>3.0)) β€’ Piotroski F-Score 3/9

β–Ό #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

πŸ“ˆ PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 β†’ Q2 β†’ Q3 β†’ Current
Q1 (-3Q)
37
Grade E$5.35-0.2% Next Q
Q2 (-2Q)
40
Grade D$5.34+12% Next Q
Q3 (-1Q)
42
Grade D$5.98-3.5% Next Q
Current
45
Grade D$5.77-6.3% Hist 90D Ξ±
Trajectory: E (37) β†’ D (45)Full Audit β†’
βš”οΈ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

βš”οΈ Adversarial Opposing Case: What Could Spark a CTKB Turnaround Squeeze

Gideon Ashmere Forensic Desk β†’

While CTKB currently carries a cautious 45/100 (D) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

πŸš€ Contrarian Squeeze Trigger #1

Big institutional funds and options desks are actively positioning on the bullish side.

πŸš€ Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($5.34) and Max Pain ($6.06) forces dealer call-delta covering toward $6.66.

πŸš€ Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $CTKBβ€’ $2.4M Crowd Pool β€’ Kalshi / Polymarket Composite
Contract: β€œCTKB Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 45%NO 55%Trade / Inspect Odds β†’
RSI-14 MOMENTUMBULLISH MOMENTUM
62.630 Oversold Β· 70 Hot
ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)
4.76>3.0 Fortress Safe
PIOTROSKI F-SCOREWEAK QUALITY (1–4)
3 / 99-Pt Accounting
52-WEEK LASER RANGE81% OF RANGE
L: $3$5.77H: $6
1. Money & Cash Health● WEAK
Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: D-RQD 7 / 20
2. Big Money & Insiders● TRIMMING
Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: DRQD 19 / 40
3. Hidden Risks & Market Weather● WARNING
SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: DRQD 19 / 40
MULTI-MODEL QUANT PANEL DELIBERATION

2-of-3 Quant Analysts Bearish Warning on CTKB

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
BEARISH (35)

-12.7% ROIC with 51.8% gross margin and -1.07% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
NEUTRAL (55)

Altman-Z 4.76 and Piotroski 3/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BEARISH (45)

19/40 institutional & smart-money positioning score with 8/20 macro alignment.

Bull Case: Why Buyers Like CTKB
  • βœ“Big institutional funds and options desks are actively positioning on the bullish side.
Bear Case: What Could Go Wrong
  • !Company executives have done more routine share selling than personal cash buying lately.
  • !Sensitive to high interest rates and tighter Federal Reserve market liquidity.
  • !Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.
ON-DEMAND RQD QUANT WORKSHOP β€’ SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring CTKB)

  • βœ“Walkthrough of CTKB's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • βœ“3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • βœ“Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) β†’$100K Arena
CTKB // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +23.82%β–² ASCENDING CHANNEL
2026-11-03O $6.30H $6.30L $5.77C $5.77VOL 1.87M
RES: $6.63SUP: $4.85SMA50: $5.34SMA200: $4.66
$6.55$5.67$4.79$3.92$3.04RES $6.63SUP $4.85$5.772026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

CTKB Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

πŸ¦‹ CTKB Butterfly Map β†’ + Track CTKB β†’
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +0.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on CTKB today. View full Setup Ledger β†’

πŸ¦‹ Documented & Second-Order Butterfly Connections Open Graph β†’

No direct multi-tier Butterfly edges indexed yet for CTKB. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for CTKB today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk β†’
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT β€’ SEC EDGAR XBRL Γ— RQD PEER BENCHMARK

πŸ“Š Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CTKB)

Health Care Rank #363 of 1015 βš”οΈ PACB vs CTKB Full Matrix β†’

1. Head-to-Head Health Care Peer Comparison (CTKB vs. PACB, NAUT, ALMR, LAB)

Industry: Biotechnology: Laboratory Analytical Instruments (21 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Cytek Biosciences Inc. (CTKB) ranks #363 by composite RQD confidence (45/100, grade D) and #382 by equity capitalization ($796.8M). Within this direct 5-issuer industry benchmark cohort, CTKB leads on earnings valuation at N/A trailing P/E, while CTKB leads on capital efficiency and profitability with -12.7% ROIC and 51.8% gross margin. ALMR currently holds the highest overall quantitative score in the immediate peer group at 55/100 (D+) compared with CTKB at 45/100 (D).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
CTKB ACTIVE
Cytek Biosciences Inc.
D 45/100 β€” 51.8% -12.7% -5.87% $796.8M Benchmark Subject
PACB
Pacific Biosciences of California Inc.
D 44/100 β€” 28.6% -35.0% -9.98% $809.7M /pacb-vs-ctkb β†’
NAUT
Nautilus Biotechnology Inc.
D- 43/100 β€” β€” -35.0% -14.47% $347.7M /naut-vs-ctkb β†’
ALMR
Alamar Biosciences Inc.
D+ 55/100 β€” β€” β€” -5.42% $2.12B /almr-vs-ctkb β†’
LAB
Standard BioTools Inc.
E 27/100 β€” 49.9% -28.7% -0.02% $240.7M /lab-vs-ctkb β†’

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K β€’ FILED 2025-12-31 β€’ CIK 0001831915 β†—

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Cytek Biosciences Inc. (CTKB) reported GAAP revenue of $201.5M (+0.5% vs. FY2024 revenue of $200.5M , and +4.4% cumulative change since FY2023) , GAAP net income of -$66.5M, operating cash flow of -$4.7M, and free cash flow of -$8.8M (-140.1% YoY). On the balance sheet, CTKB closed FY2025 with $461.5M in total assets against $0 in total debt (Altman Z-Score: 4.76, Piotroski F-Score: 3/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $201.5M -$66.5M -$4.7M -$8.8M $461.5M β€”
FY2024 (FY) 2024-12-31 $200.5M -$6.0M $25.4M $21.9M $499.5M β€”
FY2023 (FY) 2023-12-31 $193.0M -$12.1M $5.3M $5.3M β€” β€”

3. CTKB Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

βœ“ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is CTKB stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Cytek Biosciences Inc. (NASDAQ: CTKB) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 45/100 at a spot price of $5.77 (-5.87% 1D, market cap $796.8M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 16/20, SEC Balance-Sheet Forensics 11/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, CTKB ranks #363 in composite RQD confidence.

How does CTKB compare to PACB and NAUT in the Health Care sector?

Within the Health Care sector (Biotechnology: Laboratory Analytical Instruments), CTKB carries a Roarable D (45/100 RQD), trailing P/E of N/A, gross margin of 51.8%, and ROIC of -12.7%. By comparison, PACB (Pacific Biosciences of California Inc.) holds a D grade (44/100 RQD, P/E N/A, ROIC -35.0%, cap $809.7M) and NAUT (Nautilus Biotechnology Inc.) posts a D- grade (43/100 RQD, P/E N/A, ROIC -35.0%, cap $347.7M). Among the 5-stock peer group, CTKB leads on earnings multiple (N/A) while CTKB leads on capital efficiency (-12.7% ROIC).

What are the biggest fundamental strengths and SEC risk factors for CTKB?

Per CTKB's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001831915), Cytek Biosciences Inc. generated $201.5M in revenue (+0.5% YoY), -$66.5M in net income, and -$8.8M in free cash flow against $461.5M in total assets and $0 in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is CTKB trading relative to its 50-day, 200-day, and 52-week technical levels?

CTKB last traded at $5.77 (-5.87% on volume of 1,542,449 shares), positioning the stock +8.05% above its 50-day simple moving average ($5.34) and +23.82% above its 200-day simple moving average ($4.66). Across its 52-week range of $3.31 to $6.34, CTKB sits at the 81.2% percentile with a 14-day RSI of 62.6 (BULLISH MOMENTUM) and an implied next-earnings move of Β±10.3% ($5.18 to $6.36).

Direct Sub-Reports: CTKB RQD Cockpit CTKB 12M Forecast CTKB Earnings & Move CTKB Dividends & DRIP CTKB Insiders & 13F CTKB Whale Options CTKB Profit Sankey CTKB News & Why
ROARABLE RATING BRIEF β€’ RQD 45/100 (D) βœ“ SEC XBRL & RQD VERIFIED

CTKB β€” Cytek Biosciences Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Cytek Biosciences Inc. (CTKB) earns a live Roarable RQD composite score of 45/100, corresponding to a D letter grade (Roarable Sell) at a spot price of $5.77 (-5.87% 1D, market capitalization $796.8M).

  • Fundamental Cash Engine (7/20): Anchored by return on invested capital (ROIC) of -12.7%, gross margin of 51.8%, operating margin of -20.0%, and free cash flow yield of -1.07%.
  • Whale 13F & Options Flow (16/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (8/20) + Forensic Balance Sheet (11/20): Incorporates a 1.00x equity beta, Altman Z-Score of 4.76, Piotroski F-Score of 3/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Cytek Biosciences Inc. Is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Laboratory Analytical Instruments industry. It has a market capitalization of $0.8B. Per the financials, FY 2025 revenue was $201.5M.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Cytek Biosciences Inc. (CTKB) reported $201.5M in annual revenue (up from $200.5M in FY2024, +0.5% YoY) and -$66.5M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($193.0M revenue, -$12.1M net income) through FY2025, CTKB scaled operating cash flow to -$4.7M and free cash flow to -$8.8M, backed by $461.5M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • πŸ‚ Primary Bull Case (D β€’ RQD 45/100): Big institutional funds and options desks are actively positioning on the bullish side. Free cash flow yield of -1.07% and institutional whale pillar of 16/20. With Fundamental Cash Engine at 7/20 and Institutional Whale Flow at 16/20, sustained execution supports upside toward the upper end of the $3.31 – $6.34 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -20.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: Laboratory Analytical Instruments (Health Care), CTKB carries a macro regime beta of 1.00 and gross margin of 51.8%.

  • Key Question #1: Can CTKB sustain or expand its -20.0% operating margin and -12.7% ROIC against Biotechnology: Laboratory Analytical Instruments peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $201.5M and free cash flow of -$8.8M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is CTKB's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

CTKB Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Cytek Biosciences Inc. (CTKB) β€’ Click "Debate This Headline" to argue it in the Roar Pit below

πŸ’¬ Jump to CTKB Debate Forum (3) ↓
πŸ”₯ THE ROAR PIT β€’ LIVE COMMUNITY DEBATE 3 Active Posts & Replies

CTKB Bull vs. Bear Conversation Board β€” What's Your Call at $5.77?

πŸ‚ 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON CTKB 🐻 33% BEARISH CONVICTION
1. Pick Your Side on CTKB:
πŸ’‘ Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
QU QuantViper RQD DEBATE OPENER β€’ Systematic Momentum Desk πŸ‚ BULLISH 🎯 Target: $7.48 (+22.0%)
πŸ“Œ Pinned Debate

Institutional accumulation and options positioning score 16 of 20, the strongest pillar in the RQD rating.

Picked up a starter position in CTKB in my $100K Virtual Cash book at $6.13. Institutional accumulation and options positioning score 16 of 20, the strongest pillar in the RQD rating.. Trading inside a $3.31–$6.34 52-week range with -1.07% FCF yield gives solid downside support if Biotechnology: Laboratory Analytical Instruments multiples expand this quarter.

VolSurface_Trader πŸ‚ BULL

Both sides have a point here β€” CTKB's 11/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

MU MultipleCompression RQD DEBATE OPENER β€’ Valuation Discipline 🐻 BEARISH 🎯 Target: $4.97 (-18.9%)
Spot @ $6.13

ROIC of -12.7% and FCF yield of -1.07% show the company is not currently generating returns or cash for shareholders.

Careful chasing CTKB at $6.13. ROIC of -12.7% and FCF yield of -1.07% show the company is not currently generating returns or cash for shareholders.. Gross margin is 51.8%, but operating margin is -20.0%, which shows SG&A and reinvestment are eating into bottom-line EPS. Target $4.97 on multiple compression.

LIVE TAPE